Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells.

Cancer & metabolism

Zheng L, MacKenzie ED, Karim SA, Hedley A, Blyth K, Kalna G, Watson DG, Szlosarek P, Frezza C, Gottlieb E.
PMID: 24280230
Cancer Metab. 2013 Mar 21;1(1):12. doi: 10.1186/2049-3002-1-12.

BACKGROUND: Loss of function of fumarate hydratase (FH), the mitochondrial tumor suppressor and tricarboxylic acid (TCA) cycle enzyme, is associated with a highly malignant form of papillary and collecting duct renal cell cancer. The accumulation of fumarate in these...

Cite
Zheng L, MacKenzie ED, Karim SA, et al. Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells. Cancer Metab. 2013;1(1):12doi: 10.1186/2049-3002-1-12.
Zheng, L., MacKenzie, E. D., Karim, S. A., Hedley, A., Blyth, K., Kalna, G., Watson, D. G., Szlosarek, P., Frezza, C., & Gottlieb, E. (2013). Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells. Cancer & metabolism, 1(1), 12. https://doi.org/10.1186/2049-3002-1-12
Zheng, Liang, et al. "Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells." Cancer & metabolism vol. 1,1 (2013): 12. doi: https://doi.org/10.1186/2049-3002-1-12
Zheng L, MacKenzie ED, Karim SA, Hedley A, Blyth K, Kalna G, Watson DG, Szlosarek P, Frezza C, Gottlieb E. Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells. Cancer Metab. 2013 Mar 21;1(1):12. doi: 10.1186/2049-3002-1-12. PMID: 24280230; PMCID: PMC4108060.
Copy Download .nbib Format: NLM
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply.

The Lancet. Oncology

Fennell DA, Griffiths G, Ottensmeier C, Hanna GG, Danson S, Szlosarek P, Nye M.
PMID: 34973224
Lancet Oncol. 2022 Jan;23(1):e14-e15. doi: 10.1016/S1470-2045(21)00722-1.

No abstract available.

Cite
Fennell DA, Griffiths G, Ottensmeier C, et al. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply. Lancet Oncol. 2022;23(1):e14-e15doi: 10.1016/S1470-2045(21)00722-1.
Fennell, D. A., Griffiths, G., Ottensmeier, C., Hanna, G. G., Danson, S., Szlosarek, P., & Nye, M. (2022). CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply. The Lancet. Oncology, 23(1), e14-e15. https://doi.org/10.1016/S1470-2045(21)00722-1
Fennell, Dean A, et al. "CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply." The Lancet. Oncology vol. 23,1 (2022): e14-e15. doi: https://doi.org/10.1016/S1470-2045(21)00722-1
Fennell DA, Griffiths G, Ottensmeier C, Hanna GG, Danson S, Szlosarek P, Nye M. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply. Lancet Oncol. 2022 Jan;23(1):e14-e15. doi: 10.1016/S1470-2045(21)00722-1. PMID: 34973224.
Copy Download .nbib Format: NLM
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms.

JTO clinical and research reports

Szlosarek PW, Phillips MM, Pavlyk I, Steele J, Shamash J, Spicer J, Kumar S, Pacey S, Feng X, Johnston A, Bomalaski J, Moir G, Lau K, Ellis S, Sheaff M.
PMID: 34589965
JTO Clin Res Rep. 2020 Sep 03;1(4):100093. doi: 10.1016/j.jtocrr.2020.100093. eCollection 2020 Nov.

INTRODUCTION: Pegargiminase (ADI-PEG 20; ADI) degrades arginine and potentiates pemetrexed (Pem) cytotoxicity in argininosuccinate synthetase 1 (ASS1)-deficient malignant pleural mesothelioma (MPM). We conducted a phase 1 dose-expansion study at the recommended phase 2 dose of ADI-PEG 20 with Pem...

Cite
Szlosarek PW, Phillips MM, Pavlyk I, et al. Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms. JTO Clin Res Rep. 2020;1(4):100093doi: 10.1016/j.jtocrr.2020.100093.
Szlosarek, P. W., Phillips, M. M., Pavlyk, I., Steele, J., Shamash, J., Spicer, J., Kumar, S., Pacey, S., Feng, X., Johnston, A., Bomalaski, J., Moir, G., Lau, K., Ellis, S., & Sheaff, M. (2020). Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms. JTO clinical and research reports, 1(4), 100093. https://doi.org/10.1016/j.jtocrr.2020.100093
Szlosarek, Peter W, et al. "Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms." JTO clinical and research reports vol. 1,4 (2020): 100093. doi: https://doi.org/10.1016/j.jtocrr.2020.100093
Szlosarek PW, Phillips MM, Pavlyk I, Steele J, Shamash J, Spicer J, Kumar S, Pacey S, Feng X, Johnston A, Bomalaski J, Moir G, Lau K, Ellis S, Sheaff M. Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms. JTO Clin Res Rep. 2020 Sep 03;1(4):100093. doi: 10.1016/j.jtocrr.2020.100093. eCollection 2020 Nov. PMID: 34589965; PMCID: PMC8474273.
Copy Download .nbib Format: NLM
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma.

Oncoimmunology

Karydis I, Chan PY, Wheater M, Arriola E, Szlosarek PW, Ottensmeier CH.
PMID: 27467964
Oncoimmunology. 2016 Feb 18;5(5):e1143997. doi: 10.1080/2162402X.2016.1143997. eCollection 2016 May.

BACKGROUND: Untreated metastatic uveal melanoma (UM) carries a grave prognosis. Unlike cutaneous melanoma (CM), there are no established treatments known to significantly improve outcomes for a meaningful proportion of patients. Inhibition of the PD1-PDL1 axis has shown promise in...

Cite
Karydis I, Chan PY, Wheater M, et al. Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology. 2016;5(5):e1143997doi: 10.1080/2162402X.2016.1143997.
Karydis, I., Chan, P. Y., Wheater, M., Arriola, E., Szlosarek, P. W., & Ottensmeier, C. H. (2016). Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology, 5(5), e1143997. https://doi.org/10.1080/2162402X.2016.1143997
Karydis, Ioannis, et al. "Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma." Oncoimmunology vol. 5,5 (2016): e1143997. doi: https://doi.org/10.1080/2162402X.2016.1143997
Karydis I, Chan PY, Wheater M, Arriola E, Szlosarek PW, Ottensmeier CH. Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology. 2016 Feb 18;5(5):e1143997. doi: 10.1080/2162402X.2016.1143997. eCollection 2016 May. PMID: 27467964; PMCID: PMC4910726.
Copy Download .nbib Format: NLM
Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.

Cancer research and treatment

Phillips MM, Sheaff MT, Szlosarek PW.
PMID: 24453997
Cancer Res Treat. 2013 Dec;45(4):251-62. doi: 10.4143/crt.2013.45.4.251. Epub 2013 Dec 31.

Arginine deprivation is a novel antimetabolite strategy for the treatment of arginine-dependent cancers that exploits differential expression and regulation of key urea cycle enzymes. Several studies have focused on inactivation of argininosuccinate synthetase 1 (ASS1) in a range of...

Cite
Phillips MM, Sheaff MT, Szlosarek PW. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat. 2013;45(4):251-62doi: 10.4143/crt.2013.45.4.251.
Phillips, M. M., Sheaff, M. T., & Szlosarek, P. W. (2013). Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer research and treatment, 45(4), 251-62. https://doi.org/10.4143/crt.2013.45.4.251
Phillips, Melissa M, et al. "Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges." Cancer research and treatment vol. 45,4 (2013): 251-62. doi: https://doi.org/10.4143/crt.2013.45.4.251
Phillips MM, Sheaff MT, Szlosarek PW. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat. 2013 Dec;45(4):251-62. doi: 10.4143/crt.2013.45.4.251. Epub 2013 Dec 31. PMID: 24453997; PMCID: PMC3893322.
Copy Download .nbib Format: NLM
Optimizing arginine deprivation for hard-to-treat cancers.

Oncotarget

Khadeir R, Szyszko T, Szlosarek PW.
PMID: 29228540
Oncotarget. 2017 Oct 27;8(57):96468-96469. doi: 10.18632/oncotarget.22099. eCollection 2017 Nov 14.

No abstract available.

Cite
Khadeir R, Szyszko T, Szlosarek PW. Optimizing arginine deprivation for hard-to-treat cancers. Oncotarget. 2017;8(57):96468-96469doi: 10.18632/oncotarget.22099.
Khadeir, R., Szyszko, T., & Szlosarek, P. W. (2017). Optimizing arginine deprivation for hard-to-treat cancers. Oncotarget, 8(57), 96468-96469. https://doi.org/10.18632/oncotarget.22099
Khadeir, Ramsay, et al. "Optimizing arginine deprivation for hard-to-treat cancers." Oncotarget vol. 8,57 (2017): 96468-96469. doi: https://doi.org/10.18632/oncotarget.22099
Khadeir R, Szyszko T, Szlosarek PW. Optimizing arginine deprivation for hard-to-treat cancers. Oncotarget. 2017 Oct 27;8(57):96468-96469. doi: 10.18632/oncotarget.22099. eCollection 2017 Nov 14. PMID: 29228540; PMCID: PMC5722492.
Copy Download .nbib Format: NLM
Design and construction of a simplified, gas-driven, pressure-controlled emergency ventilator.

African journal of emergency medicine : Revue africaine de la medecine d'urgence

Szlosarek R, Teichert R, Wetzel A, Fichtner A, Reuter F, Kröger M.
PMID: 33194539
Afr J Emerg Med. 2021 Mar;11(1):175-181. doi: 10.1016/j.afjem.2020.09.018. Epub 2020 Nov 07.

INTRODUCTION: Due to the COVID-19 crisis or any other mass casualty situation it might be necessary to give artificial ventilation to many affected patients. Contrarily, the worldwide availability of emergency ventilators is still a shortage, especially in developing countries.METHODS:...

Cite
Szlosarek R, Teichert R, Wetzel A, et al. Design and construction of a simplified, gas-driven, pressure-controlled emergency ventilator. Afr J Emerg Med. 2020;11(1):175-181doi: 10.1016/j.afjem.2020.09.018.
Szlosarek, R., Teichert, R., Wetzel, A., Fichtner, A., Reuter, F., & Kröger, M. (2021). Design and construction of a simplified, gas-driven, pressure-controlled emergency ventilator. African journal of emergency medicine : Revue africaine de la medecine d'urgence, 11(1), 175-181. https://doi.org/10.1016/j.afjem.2020.09.018
Szlosarek, R, et al. "Design and construction of a simplified, gas-driven, pressure-controlled emergency ventilator." African journal of emergency medicine : Revue africaine de la medecine d'urgence vol. 11,1 (2021): 175-181. doi: https://doi.org/10.1016/j.afjem.2020.09.018
Szlosarek R, Teichert R, Wetzel A, Fichtner A, Reuter F, Kröger M. Design and construction of a simplified, gas-driven, pressure-controlled emergency ventilator. Afr J Emerg Med. 2021 Mar;11(1):175-181. doi: 10.1016/j.afjem.2020.09.018. Epub 2020 Nov 07. PMID: 33194539; PMCID: PMC7648187.
Copy Download .nbib Format: NLM
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply.

The Lancet. Oncology

Fennell DA, Griffiths G, Ottensmeier C, Hanna GG, Danson S, Szlosarek P, Nye M.
PMID: 34973224
Lancet Oncol. 2022 Jan;23(1):e14-e15. doi: 10.1016/S1470-2045(21)00722-1.

No abstract available.

Cite
Fennell DA, Griffiths G, Ottensmeier C, et al. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply. Lancet Oncol. 2022;23(1):e14-e15doi: 10.1016/S1470-2045(21)00722-1.
Fennell, D. A., Griffiths, G., Ottensmeier, C., Hanna, G. G., Danson, S., Szlosarek, P., & Nye, M. (2022). CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply. The Lancet. Oncology, 23(1), e14-e15. https://doi.org/10.1016/S1470-2045(21)00722-1
Fennell, Dean A, et al. "CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply." The Lancet. Oncology vol. 23,1 (2022): e14-e15. doi: https://doi.org/10.1016/S1470-2045(21)00722-1
Fennell DA, Griffiths G, Ottensmeier C, Hanna GG, Danson S, Szlosarek P, Nye M. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply. Lancet Oncol. 2022 Jan;23(1):e14-e15. doi: 10.1016/S1470-2045(21)00722-1. PMID: 34973224.
Copy Download .nbib Format: NLM
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.

Cancer medicine

Szlosarek PW, Wimalasingham AG, Phillips MM, Hall PE, Chan PY, Conibear J, Lim L, Rashid S, Steele J, Wells P, Shiu CF, Kuo CL, Feng X, Johnston A, Bomalaski J, Ellis S, Grantham M, Sheaff M.
PMID: 34382365
Cancer Med. 2021 Oct;10(19):6642-6652. doi: 10.1002/cam4.4196. Epub 2021 Aug 12.

INTRODUCTION: We evaluated the arginine-depleting enzyme pegargiminase (ADI-PEG20; ADI) with pemetrexed (Pem) and cisplatin (Cis) (ADIPemCis) in ASS1-deficient non-squamous non-small cell lung cancer (NSCLC) via a phase 1 dose-expansion trial with exploratory biomarker analysis.METHODS: Sixty-seven chemonaïve patients with advanced...

Cite
Szlosarek PW, Wimalasingham AG, Phillips MM, et al. Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer. Cancer Med. 2021;10(19):6642-6652doi: 10.1002/cam4.4196.
Szlosarek, P. W., Wimalasingham, A. G., Phillips, M. M., Hall, P. E., Chan, P. Y., Conibear, J., Lim, L., Rashid, S., Steele, J., Wells, P., Shiu, C. F., Kuo, C. L., Feng, X., Johnston, A., Bomalaski, J., Ellis, S., Grantham, M., & Sheaff, M. (2021). Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer. Cancer medicine, 10(19), 6642-6652. https://doi.org/10.1002/cam4.4196
Szlosarek, Peter W, et al. "Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer." Cancer medicine vol. 10,19 (2021): 6642-6652. doi: https://doi.org/10.1002/cam4.4196
Szlosarek PW, Wimalasingham AG, Phillips MM, Hall PE, Chan PY, Conibear J, Lim L, Rashid S, Steele J, Wells P, Shiu CF, Kuo CL, Feng X, Johnston A, Bomalaski J, Ellis S, Grantham M, Sheaff M. Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer. Cancer Med. 2021 Oct;10(19):6642-6652. doi: 10.1002/cam4.4196. Epub 2021 Aug 12. PMID: 34382365; PMCID: PMC8495293.
Copy Download .nbib Format: NLM
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.

Cancer medicine

Szlosarek PW, Wimalasingham AG, Phillips MM, Hall PE, Chan PY, Conibear J, Lim L, Rashid S, Steele J, Wells P, Shiu CF, Kuo CL, Feng X, Johnston A, Bomalaski J, Ellis S, Grantham M, Sheaff M.
PMID: 34382365
Cancer Med. 2021 Oct;10(19):6642-6652. doi: 10.1002/cam4.4196. Epub 2021 Aug 12.

INTRODUCTION: We evaluated the arginine-depleting enzyme pegargiminase (ADI-PEG20; ADI) with pemetrexed (Pem) and cisplatin (Cis) (ADIPemCis) in ASS1-deficient non-squamous non-small cell lung cancer (NSCLC) via a phase 1 dose-expansion trial with exploratory biomarker analysis.METHODS: Sixty-seven chemonaïve patients with advanced...

Cite
Szlosarek PW, Wimalasingham AG, Phillips MM, et al. Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer. Cancer Med. 2021;10(19):6642-6652doi: 10.1002/cam4.4196.
Szlosarek, P. W., Wimalasingham, A. G., Phillips, M. M., Hall, P. E., Chan, P. Y., Conibear, J., Lim, L., Rashid, S., Steele, J., Wells, P., Shiu, C. F., Kuo, C. L., Feng, X., Johnston, A., Bomalaski, J., Ellis, S., Grantham, M., & Sheaff, M. (2021). Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer. Cancer medicine, 10(19), 6642-6652. https://doi.org/10.1002/cam4.4196
Szlosarek, Peter W, et al. "Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer." Cancer medicine vol. 10,19 (2021): 6642-6652. doi: https://doi.org/10.1002/cam4.4196
Szlosarek PW, Wimalasingham AG, Phillips MM, Hall PE, Chan PY, Conibear J, Lim L, Rashid S, Steele J, Wells P, Shiu CF, Kuo CL, Feng X, Johnston A, Bomalaski J, Ellis S, Grantham M, Sheaff M. Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer. Cancer Med. 2021 Oct;10(19):6642-6652. doi: 10.1002/cam4.4196. Epub 2021 Aug 12. PMID: 34382365; PMCID: PMC8495293.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries